ArticlePloS one2018

Accounting for tumor heterogeneity when using CRISPR-Cas9 for cancer progression and drug sensitivity studies.

Jessica F Olive et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.